| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 6.1MM | - |
| Gross Profit | 1.2MM | - |
| Cost Of Revenue | 4.9MM | +33% |
| Operating Income | -19MM | -4% |
| Operating Expenses | 20.2MM | - |
| Net Income | -24.1MM | +18% |
| R&D | 12.8MM | -0% |
| G&A | - | - |
| Marketing | - | - |
| Interest Expense | 2.4MM | +5% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
GERMANTOWN, Md., March 08, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes ("ATTD") in Florence, Italy.
GERMANTOWN, Md., March 06, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
Senseonics Holdings, Inc. (AMEX:SENS) Q4 2023 Earnings Call Transcript February 29, 2024 Senseonics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.04. SENS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good evening and welcome to the […]
Q4 2023 Senseonics Holdings Inc Earnings Call
Senseonics (SENS) delivered earnings and revenue surprises of 25% and 4.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GERMANTOWN, Md., February 29, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2023.
GERMANTOWN, Md., February 15, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.
Three Medicare Administrative Contractors will start covering the Eversense E3 CGM for people who only take basal insulin.
Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable C